Summary
The disappearance of methotrexate (MTX) from serum was studied using H3-MTX. The overall elimination half-life (MTX T 1/2) was well defined from one to about six hours after i.v. administration; in 25 patients it ranged from 102 min to 750 min and was inversely related to endogenous creatinine clearance, which ranged from 6 to 140 ml/min. The corresponding apparent volume of distribution, V, obtained by extrapolation tended to decrease at lower levels of renal function. The total clearance of MTX calculated in this period varied linearly with creatinine clearance. In patients with normal serum creatinine concentration, the half-life increased with advancing age, which reflects the concurrent age-dependent decrease in creatinine production and renal function. This illustrates the need for knowledge of renal function, not based solely on serum creatinine concentration, in patients treated with methotrexate or other drugs eliminated by the kidneys. In 9 patients the results were not affected by treatment with diuretics (furosemide, hydroflumethiazide). In four patients serum MTX concentration was measured for up to 24–72 hours. An increasing half-life of MTX with time was found, suggesting that the elimination kinetics of the drug would be most adequately described by a multi-compartment model.
Similar content being viewed by others
References
Kunin, M.C.: A guide to use of antibiotics in patients with renal disease. Ann. intern. Med.67 151–158 (1967)
Dettli, L., Spring, P., Ryter, S.: Multiple dose kinetics and drug dosage in patients with kidney disease. Acta pharmacol. (Kbh.)29 211–224 (1967)
Freeman, M.V.: The fluorometric measurement of the absorption, distribution and excretion of single doses of 4-amino-10-methyl pteroylglutamic acid (aminopterin) in man. J. Pharmacol. exp. Ther.122 154–162 (1958)
Henderson, E.S., Adamson, R.H., Oliverio, V.T.: The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Res.25 1018–1024 (1965)
Huffman, D.H., Wan, S.H., Azarnoff, D.L., Hoogstraten, B.: Pharmacokinetics of methotrexate. Clin. Pharmacol. Ther.14 572–579 (1973)
Farber, S., Diamond, L.K., Mercer, R.D., Sylvester, R.F., Wolff, J.A.: Temporary remissions in acute leukemia in children produced by the folic acid antagonist, 4-amino-pteroylglutamic acid (aminopterin). New Engl. J. Med.238 787–793 (1948)
Li, M.C., Hertz, R., Spencer, D.B.: Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc. Soc. exp. Biol. (N.Y.)93 361–366 (1956)
Weinstein, G.D., Frost, P.: Methotrexate for psoriasis. Arch. Derm.103 33–38 (1971)
Rassner, G.: Psoriasis — ihre zytostatische Behandlung mit Amethopterin (Methotrexat). Fortschr. Med.91 381–390 (1973)
Kampmann, J.P., Siersbaek-Nielsen, K., Kristensen, M., Molhølm Hansen, J.: Variations in urinary creatinine and endogenous creatinine clearance due to age. Ugeskr. Laeg.133 2369–2372 (1971)
Siersbaek-Nielsen, K., Molhølm Hansen, J., Kampmann, J., Kristensen, M.: Rapid evaluation of creatinine clearance. Lancet1971 I 1133
Kristensen, M., Molhølm Hansen, J., Skovsted, L.: The influence of phenobarbital on the half-life of diphenylhydantoin in man. Acta med. scand.185 347–350 (1969)
Goldstein, A., Aronow, L., Kalman, S.M.: Principles of drug action. New York, Evanston, London: Harper & Row 1969
Beyer, K.H., Baer, J.E.: Physiological basis for the action of newer diuretic agents. Pharmacol. Rev.13 517–562 (1961)
Liegler, D.G., Henderson, E.S., Hahn, M.A., Oliverio, V.T.: The effect of organic acids on renal clearance of methotrexate in man. Clin. Pharmacol. Ther.10 849–857 (1969)
Halprin, K.M., Fului, K., Ohkawara, A.: Blood levels of methotrexate and the treatment of psoriasis. Arch. Derm.103 243–249 (1971)
Dahl, M.C.G., Gregory, M.M., Scheuer, P.J.: Liver damage due to methotrexate in patients with psoriasis. Br. med. J.1971 I 625–630
Weinstein, G., Roenigk, H., Maibach, H., Cosmides, J., Halprin, K., Millard, M.: Psoriasis-liver-methotrexate interactions. Arch. Derm.108 36–42 (1973)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kristensen, L.Ø., Weismann, K. & Hutters, L. Renal function and the rate of disappearance of methotrexate from serum. Eur J Clin Pharmacol 8, 439–444 (1975). https://doi.org/10.1007/BF00562319
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00562319